

Sanofi  
Form 6-K  
March 07, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2012

Commission File Number: 001-31368

**SANOFI**

(Translation of registrant's name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

Edgar Filing: Sanofi - Form 6-K

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In March 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated March 1, 2012: Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant
Exhibit 99.2	Press release dated March 5, 2012: Composition of Sanofi's Board of Directors



**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated March 1, 2012: Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant.
Exhibit 99.2	Press release dated March 5, 2012: Composition of Sanofi's Board of Directors.